Selektif Östrojen Reseptör Modülatörleri (SERM)
Özet
Meme kanseri, kadınlarda en sık görülen malignite olup tedavisinde östrojen hormonunun fonksiyonunun veya yapımının engellenmesi temel hedeftir. Tüm meme kanserlerinin %60-75'ini oluşturan hormon reseptörü (HR) pozitif tümörlerde endokrin tedavi zorunludur ve tedavi seçimi hastanın menopoz durumuna göre belirlenir. Selektif Östrojen Reseptör Modülatörleri (SERM) grubunun öncüsü olan Tamoksifen, hem premenopozal hem de postmenopozal hastalarda yaklaşık 40 yıldır başarıyla kullanılan nonsteroidal bir antiöströjendir. Meme dokusunda antiöstrojenik; kemik ve endometriyumda ise östrojenik etki gösteren bu ajan, hücre çoğalmasını durdurarak meme kanserinden ölüm riskini %30, nüks riskini ise %38 oranında azaltır. ATLAS ve aTTom gibi geniş ölçekli klinik çalışmaların verileri doğrultusunda, günümüzde standart adjuvan tedavi süresi 5 yıldan 10 yıla uzatılmıştır. Tamoksifen benzeri bir diğer SERM olan Toremifen ise postmenopozal metastatik ve opere meme kanserlerinde benzer etki ve güvenlilik profiliyle alternatif bir seçenek sunar. İlaç genellikle iyi tolere edilmekle birlikte, derin ven trombozu, endometriyal patolojiler, vajinal akıntı ve ateş basması gibi yan etkilere yol açabileceğinden hastaların düzenli jinekolojik takibi ile sağlıklı yaşam alışkanlıklarını sürdürmeleri kritik önem taşımaktadır.
Breast cancer is the most prevalent malignancy among women, and the primary objective of its hormonal treatment is to inhibit the production or function of estrogen. In hormone receptor (HR) positive tumors, which constitute 60-75% of all breast cancers, endocrine therapy is mandatory, and the choice of treatment is strictly determined by the patient's menopausal status. Tamoxifen, the cornerstone of Selective Estrogen Receptor Modulators (SERMs), is a nonsteroidal antiestrogen that has been successfully utilized for nearly 40 years in both premenopausal and postmenopausal settings. Exercising antiestrogenic effects on breast tissue while exhibiting estrogenic properties in bones and the endometrium, this agent arrests cell proliferation, thereby reducing the risk of breast cancer mortality by 30% and recurrence by 38%. Following pivotal data from large-scale clinical trials such as ATLAS and aTTom, the standard duration of adjuvant tamoxifen therapy has recently been extended from 5 years to 10 years. Toremifene, another SERM similar to tamoxifen, provides a comparable alternative with similar efficacy and safety profiles in postmenopausal patients. Although tamoxifen is generally well-tolerated, it can induce adverse effects including deep vein thrombosis, endometrial pathologies, vaginal discharge, and hot flashes, necessitating strict gynecological follow-ups and healthy lifestyle changes.
Referanslar
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E86.
Harinhand-Herdt S, Zelnak A, O'Regan R. Endocrine Therapy for Breast Cancer.In:Bland KI, Copeland III EM,eds. The Breast. Comprehensive Management of Benign and Malignant Disease. 4th ed Saunders-Elsevier; Philadelphia 2009:pp.1263-85.
Beatson G. On the treatment of carcinoma of the mamma: suggestions for a new method of treatment,with illustrative cases. Lancet1896;II:105-7.
Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962;18:387-414.
Elias AD, Bowles D, Kabos P. Adjuvan systemic Therapy. In:Jacobs L, Finlayson CA,eds. Early Diagnosis and Treatment of Cancer: Breast Cancer. Expert Consult. Series Philadelphia :Saunders; 2011.p.291-306.
Goldhirsch A,Ingle JN, Gelber RD, et al Panel members. Threshold for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009;20:1319-29.
Allison KH. Estrogen receptor expression in breast cancer: we can not ignore the shades of gray. Am J Clin Pathol 2008;130:853-54.
Breast Cancer. In NCCN Clinical Practice Guidelines in Oncology v.2.2011 National Comprehensive Cancer Network 2011.
Furr BJ, Jordan VC. Tamoxifen pharmacology and clinical uses. Pharmacol Ther 1984;25:127-205.
Robert NJ. Clinical efficacy of tamoxifen. Oncology (Williston Park). 1997;11(2 suppl 1):15-20.
Consensus Conference. Adjuvan Chemotherapy for breast cancer. JAMA 1985:254:3461-63.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvan tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
Goldhirsch A, Wood WC, Coates AS et al. Panel members. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22:1736-47.
Goldhirsch A, Winer EP, Coates AS, et al, Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 2013;24:2206-23.
Senkus E, Kyriakides S, Ohno S, Penault-llorca P, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(suppl5):vii8-vii30.
Breast Cancer. In NCCN Clinical Practice Guidelines in Oncology v.2.2011 National Comprehensive Cancer Network 2011.
Goldhırsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23.
Burstein HJ, Temin S, Anderson H, et al. Adjuvan endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline focused update. J Clin Oncol 2014;32:2255-69.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast Cancer v4.2018 (NCCN.org).
Curigliano G, Burstein HJ, P Winer E, et al. De-escalating and escalating treatments for early- stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017;28:1700-12.
AlbAİn KS, Barlow WE, Ravdin PM,, et al. Adjuvan chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine responsive, node positive breast cancer. a phase III, open label, randomized controlled trial. Lancet 2009;374:2055-63.
Oksuzoglu B, Guler N. An infertile patient with breast cancer who delivered a healthy child under adjuvan tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol. 2002;104:79
Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node negative breast cancer: updated findings from the National Surgical Adjuvan Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
Baumann CK, Castiglione-Gersch M. Estrogen receptor modulators and down regulators.optimal use in postmenopausal women with breast cancer Drugs 2007;67:2335-53.
Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, et al.Toremifene and tamoxifen are equally effective for early-stage breast cancer:first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004;15:1749-59.
Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone and combination with tamoxifen versus tamoxifen alone for adjuvan treatment of postmenopausal women with early breast cancer:first results of the ATAC randomised trial. Lancet 2002;359:2131-39.
Forbes JF, Cuzick J, Buzdar AU, et al. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Tralists' Group. Effect of anastrozole and tamoxifen as adjuvan treatment for early -stage breast cancer:100-month analysis of the ATAC trial. The Lancet Oncol 2008;9:45-53.
Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvan treatment for early-stage breast cancer:10-year analysis of the ATAC trial. The Lancet Oncol 2010;11: 113541.
Thurlimann B, Keshaviah A, Coates AS, ,et al. Breast International Group (BIG)1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353;2747-57.
Coates AS, Keshaviah A, Thurlimann B, , et al. Five years of letrozole compared with tamoxifen as initial adjuvan therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median. The Lancet Oncol 2011; 12:1101-108.
Chirgwin J, Smith I, Price KN, et al. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast Cancer Res Treat 2012;131:295-306.
Munzone E, Giobbie-Hurder A, Gusterson A, et al. Outcomes of special histotypes of breast cancer after adjuvan endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Ann Oncol 2015;26:2442-49.
Jones SE, Seynaeve C, Hasenburg A, et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvan multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res 2009;69(2 suppl1):Abstract 15.
van de Velde CJH, Rea D, Seynaeva C, et al. Adjuvan tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet 2011;377:321-31.
Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvan tamoxifen therapy beyond five years in patients with lymph-node positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 1996;88:1828-33.
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvan tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 2013;381:805-16.
Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvan tamoxifen to 10 years versus stopping at 5 years in6.953 women with early breast cancer. J Clin Oncol 2013;31:Abst 5.
Stewart HJ, Prescott RJ, Forrest AP: Scottish adjuvan tamoxifen trial: A randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-62.
Jankowitz RC, Davidson NE. Adjuvan endocrine therapy for breast cancer: How long is enough? Oncology 2013;27:1-4.
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast Cancer v1.2014 (NCCN.org).
Gray R, et al. Extended aromatase inhibitor treatment following 5 or more years of endocrine therapy: A meta-analysis of 22.192 women in 11 randomized trials. SABCS 2018; Abst GS3-03.
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology Clinical Practice Guideline:Update on Adjuvan Endocrine Therapy for Women With Hormone Receptor- Positive Breast Cancer. J Clin Oncol 2010;28:3784-96.
Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: Updated review. Ochsner Journal 2017;17:405-11.
Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvan therapy of hormone-responsive early breast cancer. Ann Oncol 2007;18:(suppl 8).viii26-viii35.
Janni W, Hepp P: Adjuvan aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 2010;36:249-61.
Monnier A. Clinical management of adverse events in adjuvan therapy for hormon-responsive early breast cancer. Ann Oncol 2007;18(suppl 8):viii36-viii44.
Hong S, Didwania A, Olopade O, et al. The expanding use of third-generation aromatase inhibitors:what the general internist needs to know. J Gen Intern Med 24(suppl 2):383-88.
Abdulhaq H, Geyer C. Safety of adjuvan endocrine therapy in postmenopausal women with breast cancer. Am J Clin Oncol 2008;31:595-605.
Goss PE. Evaluating long-term safety of aromatase inibitors. Postgraduate Institude of Medicine and Clinical Care Opti- ons Oncology 2008;1-21.
Colleoni M, Hurder G. Benefits and adverse effects of endocrine therapy. Ann Oncol 2010;21(suppl 7):vii107-vii111.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level metaanalysis of the randomised trials. Lancet 2015;386:1341-52.
Voskuil DW, van Nes JGH, Junggeburt JMC,van de Velde CJH,van Leeuwen FE, de Haes JCJM. MAİntenance of physical activity and body weight in relation to subsequent quality in postmenopausal breast cancer patients. Ann Oncol 2010;21:2094-101.
Burnstein HJ, Lacchetti C, Anderson H, et al. Adjuvan endocrine therapy for women with hormonereceptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 2019;37:423-38.
